Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies-Reference-Cited by-同舟云学术

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies

Published:2014-01-14 Issue:3 Volume:23 Page:268-277
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Chawla Anita J.¹,Mytelka Daniel S.²,McBride Stephan D.¹,Nellesen Dave¹,Elkins Benjamin R.¹³,Ball Daniel E.²,Kalsekar Anupama²⁴,Towse Adrian⁵,Garrison Louis P.⁶

Affiliation:

1. Analysis Group, Inc. Menlo Park CA USA

2. Global Health Outcomes Eli Lilly and Company Indianapolis IN USA

3. Performance Excellence at Stanford Hospital and Clinics Stanford CA USA

4. Bristol Myers Squibb Princeton NJ USA

5. Office of Health Economics London UK

6. Department of Pharmacy University of Washington Seattle WA USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.3559

Reference39 articles.

1. Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002

2. Public Health Security and Bioterrorism Preparedness and Response Act of 2002.Pub L No 107‐188 166 Stat 5942002.

3. Center for Drug Evaluation and Research (FDA).Guidance for Industry—Development and Use of Risk Minimization Action Plans [Internet].DHHS2005. Available at:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071616.pdf[01 December 2009].

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit–Risk Models: The Example of Rotavirus Vaccination in France;Clinical Therapeutics;2020-10

2. Individualisation du traitement de l’hyperglycémie du diabète de type 2 : choix selon la classe thérapeutique, ou selon la molécule;Médecine des Maladies Métaboliques;2017-03

3. Integration of PKPD relationships into benefit-risk analysis;British Journal of Clinical Pharmacology;2015-07-29

4. The Late Development of a New Drug;Global New Drug Development;2014-07-18